Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors

Collection

MeSH Terms

Adenocarcinoma of Lung (C04.557.470.200.025.022); Carcinoma, Non-Small-Cell Lung (C04.588.894.797.520.109.220.249); Lung neoplasms (C04.588.894.797.520); Carcinoma, Bronchogenic (C04.588.894.797.520.109.220); "Genes, erbB-1" (G05.360.340.024.340.375.500.791.295.300); "ErbB Receptors" (D08.811.913.696.620.682.725.400.009); "Proto-Oncogene proteins p21(ras)" (D08.811.277.040.330.300.400.500.600); "Anaplastic lymphoma kinase” (D08.811.913.696.620.682.725.400.002); "Proto-oncogene proteins" (D12.776.624.664.700); "Proto-oncogene proteins B-raf" (D08.811.913.696.620.682.700.559.842.374); "Receptor, trkA" (D08.811.913.696.620.682.725.400.660); "Receptor, trkB" (D08.811.913.696.620.682.725.400.700); "Receptor, trkC" (D08.811.913.696.620.682.725.400.800); "Proto-oncogene proteins c-met" (D08.811.913.696.620.682.725.400.075); "Proto-oncogene proteins c-ret" (D08.811.913.696.620.682.725.400.087); Receptor, ErbB-2 (D08.811.913.696.620.682.725.400.009.400); Proto-oncogene proteins c-akt (D08.811.913.696.620.682.700.755); Discoidin Domain Receptor 2 (D08.811.913.696.620.682.725.400.005.750); Receptor, Fibroblast growth factor, type 1 (D08.811.913.696.620.682.725.400.177); Receptor, Fibroblast growth factor, type 2 (D08.811.913.696.620.682.725.400.178); Receptor, Fibroblast growth factor, type 3 (D08.811.913.696.620.682.725.400.179); Receptor, Fibroblast growth factor, type 4 (D08.811.913.696.620.682.725.400.180); "Kelch-like ECH-associated protein 1" (D12.644.360.024.306); "MAP Kinase Kinase 1" (D08.811.913.696.620.682.700.565.100); Neuregulin-1 (D12.644.276.860.550.750); Class I Phosphatidylinositol 3-Kinases (D08.811.913.696.620.500.100.100); Tumor suppressor protein p53 (D12.776.157.687.650)

Keywords

tki, molecular testing, treatment, lung cancer patients, targeted tyrosine kinase inhibitors, cap, college of american pathologists, international association for the study of lung cancer, association for molecular pathology, guideline update, evidence-based guideline, clinical molecular testing of non-small cell lung cancers, nsclc

Record Publish Year

2018

Publication Date

Original Published: June 2013
Update Published: January 22, 2018

Expected Publication Date

Update: Q3, 2025

Guideline Contact

Christina Ventura (cventur@cap.org)

Publication Scope

assessment

Countries of Application

United States

Guideline Publication Status

Under Review

Languages

English

Authors

CAP (US)

Publication Year

2018